G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future
Glioblastoma (GBM) is one of the deadliest tumors and has a median survival of 3 months if left untreated. Despite advances in rationally targeted pharmacological approaches, the clinical care of GBM remains palliative in intent. Since the majority of altered signaling cascades involved in cancer es...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
China Anti-Cancer Association
2018-12-01
|
Series: | Cancer Biology & Medicine |
Subjects: | |
Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/1289 |